To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT06646354 · tracked via the Priya Life Science South Korea tracker

Sponsor

Hyundai Pharm

Phase

Phase 3

Started

2025-04-22

Last updated

2025-05-22

Condition(s) studied

HypertensionPrimary Hypercholesterolaemia

Investigational drug(s) / intervention(s)

Ezetimibe/Rosuvastatin/Candesartan/AmlodipineCandesartan/AmlodipineCandesartan/Rosuvastatin/Ezetimibe

Ezetimibe/Rosuvastatin/Candesartan/Amlodipine: PO, QD, 8 weeks

Candesartan/Amlodipine: PO, QD, 8 weeks

Candesartan/Rosuvastatin/Ezetimibe: PO, QD, 8 weeks

Study summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Eligibility

Sex

ALL

Min age

19 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥ 19 * Patients with Essential Hypertension and Primary Hypercholesterolemia Exclusion Criteria: * Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP * Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg

Primary outcome measure(s)

Low density lipoprotein cholesterol (LDL-C) — baseline and week 8
LDL-C change at Week 8 compared HODO-2224-1 + HODO-2224-4 + HODO-2224-5 with HODO-2224
Mean sitting systolic blood pressure (MSSBP) — baseline and week 8
MSSBP change at week 8 compared HODO-2224-2 + HODO-2224-3 + HODO-2224-6 with HODO-2224

Trial sites (1)

Facility	City	Region	Status
Hanyang University Hospital	Seoul	South Korea

More Hyundai Pharm trials in South Korea

To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise Recruiting

Other trials for the same condition

Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B Active, not recruiting

A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers Recruiting

The Effect of Home Blood Pressure Measurement on the Management of Hypertension Active, not recruiting

Validation Study of CART BP as a Wearable Cuffless Blood Pressure Monitor Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06646354 on ClinicalTrials.gov ↗ ← All trials in South Korea